

PTO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office

on December 26, 2002
Date

Deborah A. Gunkel
Signature

Deborah A. Gunkel

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

The following forms are being transmitted herewith:
Transmittal Letter, one page (in duplicate);
Combined Notice of Appeal from the Primary Examiner
to the Board of Patent Appeals and Interferences
& Petition for Extension of Time Under 36 CFR 1.136(a)
two pages (in duplicate);
Power of Attorney by Assignee of Entire Interest
(Revocation of Prior Powers), with Statement under
37 CFR 3.373(b), four pages;
Amendment and Response to Office Action, ten pages.

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TRANSMITTAL LETTER
(General - Patent Pending)Docket No.
CRI-3USIn Re Application Of: **Donald Mickle et al.**

Serial No.

09/363,100

Filing Date

July 29, 1999

Examiner

Afremova, Vera

Group Art Unit

1651


Title: **MESENCHYMAL STEM CELL TRANSPLANTATION INTO DAMAGED MYOCARDIUM****TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:**

Transmitted herewith is:

Amendment and Response to Office Action; Combined Notice of Appeal from the Primary Examiner to the Board of Patent Appeals and Interferences & Petition for Extension of Time under 37 CFR 1.136(a); Power of Attorney by Assignee of Entire Interest (Revocation of Prior Powers) with Statement under 37 CFR 3.73(b); and Certificate of Transmission under 37 CFR 1.8.

in the above identified application.

- ☐ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. **07-1074** as described below. A duplicate copy of this sheet is enclosed.
- ☒ Charge the amount of **\$1,240.00**
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.


SignatureDated: **December 26, 2002**

Madge R. Kanter
Reg. No. 35,211
GENZYME CORPORATION
One Kendall Square
Cambridge, MA 02139
Tel. (617) 761-8485
Fax (617) 252-7977

I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

*Signature of Person Mailing Correspondence**Typed or Printed Name of Person Mailing Correspondence*

CC:

Docket Number CRI-3US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Donald Mickle et al.
Serial Number : 09/363,100
Confirmation Number : 7723
Examiner : Afremova, Vera
Art Unit : 1651
Filed : July 29, 1999
For : MESENCHYMAL STEM CELL
TRANSPLANTATION INTO DAMAGED
MYOCARDIUM

Commissioner of Patents and Trademarks
United States Patent and Trademark Office
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. § 3.73(b)


Sir:

This Statement Under 37 C.F.R. § 3.73(b) accompanies a POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST, filed in the above-identified application concurrently herewith.

Evidence establishing that Genzyme Corporation is the assignee of the entire right, title and interest in the above-identified application, may be found in the Assignment recorded on December 16, 1999 at Reel 10462 and Frame 0885.

Evidence that the undersigned is authorized to act on behalf of Genzyme may be found in the attached SIGNATURE AUTHORITY.

Respectfully submitted,



Madge R. Kanter (Reg. No. 35,211)
Attorney for Applicant
Genzyme Corporation
One Kendall Square
Cambridge, Massachusetts 02139
Tel. (617) 761-8485

Dated: December 26, 2002




GENZYME CORPORATION
ONE KENDALL SQUARE
CAMBRIDGE, MA 02139-1562, U.S.A.
617-252-7500
FAX 617-252-7600

SIGNATURE AUTHORITY

I, Thomas J. DesRosier, Senior Vice President and General Counsel of Genzyme Corporation hereby appoint Madge R. Kanter, Richard Allison, Elizabeth Lassen and Bart G. Newland, all Managing Intellectual Property Counsel of Genzyme Corporation, with full power and authority to transact any and all business before the United States Patent and Trademark Office, and any foreign counterpart patent office, with the powers of a Corporate Officer of Genzyme Corporation.

Date: September 24, 2001



Thomas J. DesRosier, Esquire
Senior Vice President and General Counsel
GENZYME CORPORATION

G nzyme CorporationOne Kendall Square, 1400 Building, 4th Floor

Cambridge, Massachusetts 02139 U.S.A.

Telephone: (617) 252-7500

Facsimile: (617) 252-7977

Maggie Kanter

Direct Dial: (617) 761-8485

maggie.kanter@genzyme.com

LEGAL DEPARTMENT

FAX RECEIVED

DEC 27 2002

GROUP 1600

Facsimile**To:** Vera Afremova**From:** Maggie Kanter**Fax:** (703) 308-4242**Pages:** 22**Phone:** (703) 308-9351**Date:** 12/26/2002**Re:** CRI-3US**CC:**

Application No.: 09/363,100

Title: MESENCHYMAL STEM CELL

TRANSPLANTATION INTO

DAMAGED MYOCARDIUM

OFFICIAL**NOTICE OF CONFIDENTIALITY**

This transmission is intended only for the addressee(s) listed above, and may contain information that is confidential or privileged. If you are not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified you have received this document in error and any use, disclosure, copying or communication of the contents of this transmission is prohibited. If this message was received in error, please telephone us immediately.